4/15
09:32 am
incy
The past three years for Incyte (NASDAQ:INCY) investors has not been profitable [Yahoo! Finance]
Low
Report
The past three years for Incyte (NASDAQ:INCY) investors has not been profitable [Yahoo! Finance]
4/11
08:00 am
incy
Incyte to Report First Quarter Financial Results
Low
Report
Incyte to Report First Quarter Financial Results
4/5
07:35 pm
incy
SEC Wins Trial in Novel ‘Shadow' Insider Trading Crackdown [BNN Bloomberg (Canada)]
Low
Report
SEC Wins Trial in Novel ‘Shadow' Insider Trading Crackdown [BNN Bloomberg (Canada)]
4/1
11:14 am
incy
Top 20 S&P 500 stocks by hedge fund net exposure - BofA [Seeking Alpha]
Low
Report
Top 20 S&P 500 stocks by hedge fund net exposure - BofA [Seeking Alpha]
4/1
09:44 am
incy
Incyte and CMS collaborate for povorcitinib in Mainland China, Hong Kong, Macau, Taiwan and SEA [Seeking Alpha]
Low
Report
Incyte and CMS collaborate for povorcitinib in Mainland China, Hong Kong, Macau, Taiwan and SEA [Seeking Alpha]
4/1
08:39 am
incy
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia [Yahoo! Finance]
Low
Report
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia [Yahoo! Finance]
4/1
08:39 am
incy
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia [Yahoo! Finance]
Low
Report
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia [Yahoo! Finance]
4/1
08:30 am
incy
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
Low
Report
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
3/29
04:38 pm
incy
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
3/29
04:30 pm
incy
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
3/28
08:03 am
incy
Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope [Seeking Alpha]
Low
Report
Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope [Seeking Alpha]
3/27
12:16 pm
incy
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up [Yahoo! Finance]
Low
Report
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up [Yahoo! Finance]
3/25
11:29 am
incy
Incyte Co. (NASDAQ: INCY) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $65.00 price target on the stock.
Low
Report
Incyte Co. (NASDAQ: INCY) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $65.00 price target on the stock.
3/18
03:16 pm
incy
Incyte Co. (NASDAQ: INCY) had its price target lowered by analysts at Bank of America Co. from $69.00 to $67.00. They now have a "neutral" rating on the stock.
Low
Report
Incyte Co. (NASDAQ: INCY) had its price target lowered by analysts at Bank of America Co. from $69.00 to $67.00. They now have a "neutral" rating on the stock.
3/12
03:26 pm
incy
Incyte (INCY) Posts Positive Results on Opzelura From HS Study [Yahoo! Finance]
Neutral
Report
Incyte (INCY) Posts Positive Results on Opzelura From HS Study [Yahoo! Finance]
3/10
04:13 pm
incy
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis [Yahoo! Finance]
Low
Report
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis [Yahoo! Finance]
3/10
04:13 pm
incy
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa [Yahoo! Finance]
Low
Report
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa [Yahoo! Finance]
3/10
04:05 pm
incy
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
Low
Report
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
3/10
04:05 pm
incy
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
Low
Report
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
3/6
05:20 pm
incy
Tracking Baker Brothers Portfolio - Q4 2023 Update [Seeking Alpha]
Low
Report
Tracking Baker Brothers Portfolio - Q4 2023 Update [Seeking Alpha]
3/4
08:29 am
incy
New Data from Incyte's Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]
Low
Report
New Data from Incyte's Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]
3/4
08:00 am
incy
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
Low
Report
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
2/29
10:19 am
incy
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients' Lives through Generative AI [Yahoo! Finance]
Low
Report
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients' Lives through Generative AI [Yahoo! Finance]
2/29
10:19 am
incy
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI
Low
Report
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI
2/29
09:28 am
incy
Knight Therapeutics Announces Launch of Minjuvi® in Brazil [Canadian Business Journal (Canada)]
Medium
Report
Knight Therapeutics Announces Launch of Minjuvi® in Brazil [Canadian Business Journal (Canada)]